Splisense
Jerusalem
About Splisense
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $28.5M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2021)
- Website: splisense.com
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/splisense-3532 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.